172 related articles for article (PubMed ID: 27662818)
1. Utility of serum anti-cetuximab immunoglobulin E levels to identify patients at a high risk of severe hypersensitivity reaction to cetuximab.
Dupont B; Mariotte D; Dugué AE; Clarisse B; Grellard JM; Babin E; Chauffert B; Dakpé S; Moldovan C; Bouhier-Leporrier K; Reimund JM; Di Fiore F; Zanetta S; Mailliez A; Do P; Peytier A; Galais MP; Florescu C; Schott R; Le Mauff B; Gervais R
Br J Clin Pharmacol; 2017 Mar; 83(3):623-631. PubMed ID: 27662818
[TBL] [Abstract][Full Text] [Related]
2. Risk factors associated with hypersensitivity reactions to cetuximab: anti-cetuximab IgE detection as screening test.
Dupont B; Mariotte D; Clarisse B; Galais MP; Bouhier-Leporrier K; Grellard JM; Le Mauff B; Reimund JM; Gervais R
Future Oncol; 2014 Nov; 10(14):2133-40. PubMed ID: 25471028
[TBL] [Abstract][Full Text] [Related]
3. Anti-cetuximab IgE ELISA for identification of patients at a high risk of cetuximab-induced anaphylaxis.
Mariotte D; Dupont B; Gervais R; Galais MP; Laroche D; Tranchant A; Comby E; Bouhier-Leporrier K; Reimund JM; Le Mauff B
MAbs; 2011; 3(4):396-401. PubMed ID: 21654207
[TBL] [Abstract][Full Text] [Related]
4. A novel approach to predict cetuximab-induced hypersensitivity reaction: detection of drug-specific IgE on basophils.
Iwamoto T; Okamoto A; Ishinaga H; Shimizu K; Gayle AA; Arai N; Takeuchi K; Okuda M
Cancer Med; 2016 Jun; 5(6):1004-12. PubMed ID: 26880699
[TBL] [Abstract][Full Text] [Related]
5. A retrospective analysis of cross-reacting cetuximab IgE antibody and its association with severe infusion reactions.
Maier S; Chung CH; Morse M; Platts-Mills T; Townes L; Mukhopadhyay P; Bhagavatheeswaran P; Racenberg J; Trifan OC
Cancer Med; 2015 Jan; 4(1):36-42. PubMed ID: 25296628
[TBL] [Abstract][Full Text] [Related]
6. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose.
Chung CH; Mirakhur B; Chan E; Le QT; Berlin J; Morse M; Murphy BA; Satinover SM; Hosen J; Mauro D; Slebos RJ; Zhou Q; Gold D; Hatley T; Hicklin DJ; Platts-Mills TA
N Engl J Med; 2008 Mar; 358(11):1109-17. PubMed ID: 18337601
[TBL] [Abstract][Full Text] [Related]
7. Cetuximab infusion reactions: French pharmacovigilance database analysis.
Grandvuillemin A; Disson-Dautriche A; Miremont-Salamé G; Fourrier-Reglat A; Sgro C;
J Oncol Pharm Pract; 2013 Jun; 19(2):130-7. PubMed ID: 23154574
[TBL] [Abstract][Full Text] [Related]
8. Anti-Amoxicillin Immunoglobulin E, Histamine-2 Receptor Antagonist Therapy and Mast Cell Activation Syndrome Are Risk Factors for Amoxicillin Anaphylaxis.
Pastorello EA; Stafylaraki C; Mirone C; Preziosi D; Aversano MG; Mascheri A; Losappio LM; Ortolani V; Nichelatti M; Farioli L
Int Arch Allergy Immunol; 2015; 166(4):280-6. PubMed ID: 25968421
[TBL] [Abstract][Full Text] [Related]
9. The incidence of perioperative hypersensitivity reactions: a single-center, prospective, cohort study.
Berroa F; Lafuente A; Javaloyes G; Cabrera-Freitag P; de la Borbolla JM; Moncada R; Goikoetxea MJ; Sanz ML; Ferrer M; Gastaminza G
Anesth Analg; 2015 Jul; 121(1):117-123. PubMed ID: 25902325
[TBL] [Abstract][Full Text] [Related]
10. The role of IgE specific for galactose-α-1,3-galactose in predicting cetuximab induced hypersensitivity reaction: a systematic review and a diagnostic meta-analysis.
Lungulescu CV; Ungureanu BS; Turcu-Stiolica A; Ghimpau V; Artene SA; Cazacu IM; Grecu AF; Dinescu VC; Croitoru A; Volovat SR
Sci Rep; 2020 Dec; 10(1):21355. PubMed ID: 33288791
[TBL] [Abstract][Full Text] [Related]
11. Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions.
Vultaggio A; Matucci A; Nencini F; Pratesi S; Parronchi P; Rossi O; Romagnani S; Maggi E
Allergy; 2010 May; 65(5):657-61. PubMed ID: 19951375
[TBL] [Abstract][Full Text] [Related]
12. Validation of an anti-α-Gal IgE fluoroenzyme-immunoassay for the screening of patients at risk of severe anaphylaxis to cetuximab.
Serrier J; Davy JB; Dupont B; Clarisse B; Parienti JJ; Petit G; Khoy K; Ollivier Y; Gervais R; Mariotte D; Le Mauff B
BMC Cancer; 2023 Jan; 23(1):32. PubMed ID: 36624467
[TBL] [Abstract][Full Text] [Related]
13. Current Knowledge and Management of Hypersensitivity Reactions to Monoclonal Antibodies.
Picard M; Galvão VR
J Allergy Clin Immunol Pract; 2017; 5(3):600-609. PubMed ID: 28110056
[TBL] [Abstract][Full Text] [Related]
14. Anaphylaxis to the carbohydrate side chain alpha-gal.
Platts-Mills TA; Schuyler AJ; Tripathi A; Commins SP
Immunol Allergy Clin North Am; 2015 May; 35(2):247-60. PubMed ID: 25841549
[TBL] [Abstract][Full Text] [Related]
15. Nationwide pharmacovigilance data for cetuximab-induced anaphylaxis and predictive model validation using prospective specific IgE detection.
Park KH; Lee J; Beom SH; Shin SJ; Ahn JB; Kim SR; Lee JH; Park JW
World Allergy Organ J; 2021 Jul; 14(7):100553. PubMed ID: 34257795
[TBL] [Abstract][Full Text] [Related]
16. Low rate of cetuximab hypersensitivity reactions in Northeast Tennessee: An Appalachian effect?
Adams CB; Street DS; Crass M; Bossaer JB
J Oncol Pharm Pract; 2016 Dec; 22(6):784-789. PubMed ID: 26590031
[TBL] [Abstract][Full Text] [Related]
17. Depletion of interfering IgG and IgM is critical to determine the role of IgE in pegvaliase-associated hypersensitivity.
Larimore K; Nguyen T; Badillo B; Lau K; Zori R; Shepherd G; Zoog SJ; Weng HH; Gupta S
J Immunol Methods; 2019 May; 468():20-28. PubMed ID: 30880261
[TBL] [Abstract][Full Text] [Related]
18. Accurate assessment of alpha-gal syndrome using cetuximab and bovine thyroglobulin-specific IgE.
Sim DW; Lee JS; Park KH; Jeong KY; Ye YM; Lee JH; Park JW
Mol Nutr Food Res; 2017 Oct; 61(10):. PubMed ID: 28497612
[TBL] [Abstract][Full Text] [Related]
19. Incidence of and risk factors associated with nedaplatin-related hypersensitivity reactions.
Kawarada Y; Miyazaki M; Itoh A; Araki R; Iwamizu H; Kataoka T; Kumakura Y; Ota A; Nagai T; Yamada K
Int J Clin Oncol; 2017 Jun; 22(3):593-599. PubMed ID: 28124284
[TBL] [Abstract][Full Text] [Related]
20. High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history.
O'Neil BH; Allen R; Spigel DR; Stinchcombe TE; Moore DT; Berlin JD; Goldberg RM
J Clin Oncol; 2007 Aug; 25(24):3644-8. PubMed ID: 17704414
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
